Cite
HARVARD Citation
Lindauer, A. et al. (2017). Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab. CPT: pharmacometrics & systems pharmacology. pp. 11-20. [Online].